IDiyas

For the Inventor, By the Inventor

Tokyo, Japan

Eiichi Kitazawa

USPTO Granted Patents = 10

Average Co-Inventor Count = 6.2

ph-index = 6

Forward Citations = 107(Granted Patents)


Location History:

  • Hiromachi, JP (1989 - 1992)
  • Tokyo, JP (1987 - 2000)

Company Filing History:

goldMedal10 out of 613 
 
Sankyo Company, Limited
 patents

Years Active: 1987-2000

Loading Chart...
10 patents (USPTO):Explore Patents
1. 6040339 - Urea derivatives having ACAT inhibitory activity, their preparation and (2000-03-21),
2. 5880147 - Amide derivatives having ACAT inhibitory activity, their preparation and (1999-03-09),
3. 5827855 - Hexahydronaphthalene ester derivatives their preparation and their (1998-10-27),
4. 5614550 - Amide and urea derivatives having anti-hypercholesteremic activity, (1997-03-25),
5. 5534529 - Substituted aromatic amides and ureas derivatives having (1996-07-09),
6. 5491167 - Hexahydronaphthalene ester derivatives, their preparation and their (1996-02-13),
7. 5451688 - Hexahydronaphthalene ester derivatives, their preparation and their (1995-09-19),
8. 5104888 - Thiazolidine derivatives, their preparation and use (1992-04-14),
9. 4871762 - Lipid peroxide lowering 1,3-benzoxathiole derivative compositions and (1989-10-03),
10. 4691027 - 1,3-benzoxathiole derivatives (1987-09-01),

Title: Eiichi Kitazawa: Innovator in Pharmaceutical Chemistry

Introduction

Eiichi Kitazawa is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds with acyl-CoA: cholesterol acyl transferase (ACAT) inhibitory activity. With a total of 10 patents to his name, Kitazawa's work has the potential to impact the treatment of various health conditions.

Latest Patents

Among his latest patents, Kitazawa has developed urea derivatives that exhibit ACAT inhibitory activity. These compounds are characterized by specific structural formulas, where R groups can vary, allowing for a range of potential applications. Additionally, he has worked on amide derivatives that also demonstrate valuable inhibitory activity against ACAT, showcasing his innovative approach to pharmaceutical development.

Career Highlights

Kitazawa is currently associated with Sankyo Company, Limited, where he continues to advance his research in pharmaceutical innovations. His work has not only contributed to the scientific community but has also positioned him as a key player in the industry.

Collaborations

Throughout his career, Kitazawa has collaborated with notable colleagues such as Hiroshi Kogen and Sadao Ishihara. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical compounds.

Conclusion

Eiichi Kitazawa's contributions to pharmaceutical chemistry through his innovative patents and collaborations highlight his importance in the field. His work continues to pave the way for advancements in medical treatments and therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…